Literature DB >> 21878890

Expanding horizons in metastatic prostate cancer treatment.

Karim Fizazi, Carsten Goessl.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21878890     DOI： 10.1038/nrclinonc.2011.67-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  5 in total

Review 1.  Fully human therapeutic monoclonal antibodies.

Authors:  Louis M Weiner
Journal:  J Immunother       Date:  2006 Jan-Feb       Impact factor: 4.456

2.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

Review 3.  Bone metastasis in prostate cancer: emerging therapeutic strategies.

Authors:  Justin Sturge; Matthew P Caley; Jonathan Waxman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-10       Impact factor: 66.675

4.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

5.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.

Authors:  David P Dearnaley; Malcolm D Mason; Mahesh K B Parmar; Karen Sanders; Matthew R Sydes
Journal:  Lancet Oncol       Date:  2009-08-10       Impact factor: 41.316
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.